Overview
This document provides a comparative analysis of biosimilar regulatory guidelines across Japan (PMDA/MHLW), the European Union (EMA), and the United States (FDA). The comparison highlights key similarities and differences in regulatory expectations for biosimilar development, including reference product selection, non-clinical studies, clinical pharmacology, efficacy requirements, extrapolation of indications, and global development strategies.
Use of Foreign Reference Products
One of the major differences among the regions relates to the use of foreign-approved reference products.
In the EU and U.S., sponsors may use reference products approved outside the local jurisdiction, provided that appropriate bridging data are generated. This typically includes analytical comparisons among the proposed biosimilar, the locally approved reference product, and the foreign comparator, as well as PK and, where appropriate, PD studies.
In Japan, it is necessary to justify the comparability and identity ofthe Japanese-approved reference product and the foreign-approved reference product based on quality comparability data and other relevant evidence. In this context, the “same product” refers to a product approved under the same marketing authorization. Publicly available information including manufacturing site information, may also be utilized to support the assessment of product identity..
Increasing Flexibility in Non-Clinical Safety Requirements
Across all three regions, regulatory authorities increasingly recognize that extensive animal studies may not always be necessary when robust analytical and functional similarity has already been demonstrated.
EMA generally does not require in vivo animal studies when analytical characterization and in vitro studies provide sufficient evidence of similarity and no specific safety concerns have been identified. FDA similarly allows a reduced non-clinical package when analytical similarity is well established.
Japan also permits waiver of non-clinical safety studies when quality and pharmacological data sufficiently demonstrate high similarity and no safety concerns exist. However, additional studies may still be required if product-specific safety concerns are identified.
Clinical PK/PD Studies as the Foundation of Biosimilar Development
All three regulatory agencies place significant emphasis on comparative PK and PD studies as a highly sensitive tool for detecting potential differences between a biosimilar and its reference product.
For products approved via multiple administration routes, EMA and FDA generally consider the subcutaneous route to be the most sensitive because it evaluates both absorption and elimination characteristics and may better detect immunogenicity differences. Under certain circumstances, a subcutaneous study alone may support biosimilarity without requiring additional intravenous studies.
Japan adopts a similar scientific approach, although it generally expects evaluation of all approved administration routes unless a scientific justification supports a more limited program.
Dose Selection in PK and PD Studies
Japan generally recommends using the approved reference product dose but allows alternative doses if scientifically justified.
FDA emphasizes selecting the most sensitive dose for detecting potential differences in PK and PD characteristics. In some cases, lower doses may be more informative than therapeutic doses, particularly when nonlinear pharmacokinetics or plateau pharmacodynamic responses are present. EMA similarly allows doses below the therapeutic range in healthy volunteer studies when scientifically appropriate.
PK Similarity Assessment and Equivalence Margins
All regions utilize equivalence-based statistical approaches for comparative PK evaluations.
FDA and Japan generally recognize the conventional bioequivalence range of 80–125% based on the 90% confidence interval of primary PK parameters, although alternative margins may be justified depending on product characteristics. EMA also commonly applies this framework but emphasizes interpreting the totality of evidence rather than relying solely on statistical outcomes.
Potential Reduction of Confirmatory Efficacy Trials
A notable trend across all three regions is the growing possibility of reducing or eliminating large confirmatory efficacy trials when robust analytical, PK, and PD evidence demonstrates biosimilarity.
EMA states that confirmatory efficacy studies may not be necessary when analytical, functional, PK, PD, and safety data collectively provide compelling evidence of similar clinical performance. FDA acknowledges that convincing PK and PD data may eliminate the need for comparative efficacy studies in certain cases. Japan similarly allows efficacy studies to be waived when PK or PD data can adequately predict clinical equivalence.
This reflects a broader global movement toward a more science-driven and efficient biosimilar development paradigm.
Flexibility in Clinical Trial Endpoints
Regulators increasingly encourage the use of sensitive endpoints capable of detecting differences between products rather than requiring the exact endpoints used in originator development programs.
For example, Japan explicitly states that true clinical endpoints are not always necessary and that surrogate measures, such as objective response rate for certain oncology products, may be appropriate if they are sufficiently sensitive to demonstrate biosimilarity. FDA and EMA take a similar risk-based approach.
Acceptance of Global Clinical Data
Japan provides flexibility regarding the use of overseas clinical data. When ethnic factors are not expected to affect study outcomes, foreign clinical data may be sufficient and dedicated Japanese clinical studies may not be required. Sponsors should provide scientific justification supporting the absence of clinically meaningful ethnic differences.
Extrapolation of Indications
Extrapolation remains a key regulatory principle for biosimilars across all regions.
EMA, FDA, and Japan allow approval in multiple indications based on data generated in a single sensitive indication, provided that biosimilarity is convincingly demonstrated through the totality of evidence and the mechanism of action, safety profile, immunogenicity, and other scientific considerations support extrapolation.
Additional justification may be required when mechanisms of action differ across indications or when immunogenicity profiles may vary among patient populations.
Conclusion
The comparison demonstrates substantial convergence among Japan, the EU, and the U.S. in biosimilar regulatory expectations. All three regulators increasingly emphasize a totality-of-evidence approach, prioritize analytical and clinical pharmacology data, allow greater flexibility in non-clinical and efficacy requirements, and support scientifically justified extrapolation of indications. These evolving policies facilitate more efficient global biosimilar development while maintaining rigorous standards for quality, safety, and efficacy.
Reference